Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Posted: February 5, 2025 at 2:42 am

Dr. Jennifer Kissner, SVP Clinical Development, discusses the 12-week safety and efficacy results for NORSE EIGHT clinical trial

Read this article:
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Related Posts